Literature DB >> 28923694

Outcomes of transcatheter aortic valve replacement using a minimalist approach.

Sergey Gurevich1, Brett Oestreich1, Rosemary F Kelly1, Mackenzie Mbai2, Stefan Bertog2, Karen Ringsred3, Annette Lawton3, Brenda Thooft3, Julie Wagner3, Santiago Garcia4.   

Abstract

BACKGROUND: Transcatheter Aortic Valve Replacement (TAVR) is increasingly performed using a minimalist approach under monitored anesthesia care (MAC). The safety of this approach remains controversial and adoption has been low in the US.
METHODS: The study cohort was comprised of 130 patients (98% male) who underwent TAVR between 4/2015 and 4/2017 at the Minneapolis VA. We compared the outcomes of 81 patients who underwent TAVR using a standard approach (standard TAVR) and 49 who underwent TAVR using a minimalist approach (minimalist TAVR). Outcome measures included device and procedural success, procedural efficiency, length of intensive care unit (ICU) and hospital stay, procedural complications and hospital readmissions.
RESULTS: Mean age was 80 (±9) years and median (IQR) STS score was 5 (4-6). Access included transfemoral (n = 111, 85%) and alternative (n = 19, 15%). Minimalist TAVR was associated with reduced procedural time: median 101 min (IQR: 78-135) versus 127 min (IQR: 97-182, p = 0.03), fluoroscopy time: median 18 min (IQR: 12-26) versus 24 min (IQR: 16-38), p = 0.001), contrast volume 90 ml (IQR: 70-120 ml) versus 140 ml (IQR: 86-213 ml, p < 0.001).
CONCLUSIONS: A minimalistic approach to TAVR is associated with improved procedural efficiency and reduced length of stay without compromising procedural success or clinical outcomes. Published by Elsevier Inc.

Entities:  

Keywords:  Moderate sedation; Outcomes; Transcatheter valve replacement

Mesh:

Year:  2017        PMID: 28923694     DOI: 10.1016/j.carrev.2017.08.002

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  6 in total

1.  2020 update of the Austrian Society of Cardiology (ÖKG) and the Austrian Society of Cardiac Surgery (ÖGHTG) on the position statement of the ÖKG and ÖGHTG for transcatheter aortic valve implantation 2011.

Authors:  Gudrun Lamm; Matthias Hammerer; Uta C Hoppe; Martin Andreas; Rudolf Berger; Ronald K Binder; Nikolaos Bonaros; Georg Delle-Karth; Matthias Frick; Michael Grund; Bernhard Metzler; Thomas Neunteufl; Philipp Pichler; Albrecht Schmidt; Wilfried Wisser; Andreas Zierer; Rainald Seitelberger; Michael Grimm; Alexander Geppert
Journal:  Wien Klin Wochenschr       Date:  2021-03-23       Impact factor: 1.704

Review 2.  The transition from transesophageal to transthoracic echocardiography during transcatheter aortic valve replacement: an evolving field.

Authors:  Menhel Kinno; Eric P Cantey; Vera H Rigolin
Journal:  J Echocardiogr       Date:  2018-11-21

3.  Incidence and predictors of transcatheter aortic valve replacement device emboligenic matter detected by transesophageal echocardiography.

Authors:  Masaki Yashige; Kan Zen; Shunsuke Nakamura; Tomotaka Fujimoto; Kazuaki Takamatsu; Nobuyasu Ito; Yoshito Kadoya; Michiyo Yamano; Tetsuhiro Yamano; Takeshi Nakamura; Hitoshi Yaku; Satoaki Matoba
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-24       Impact factor: 2.357

Review 4.  Advances in transcatheter aortic valve implantation, part 2: perioperative care.

Authors:  M Charlesworth; B G Williams; M H Buch
Journal:  BJA Educ       Date:  2021-03-19

5.  Simplification and optimization of transcatheter aortic valve implantation - fast-track course without compromising safety and efficacy.

Authors:  Manik Chopra; Ngai H V Luk; Ole De Backer; Lars Søndergaard
Journal:  BMC Cardiovasc Disord       Date:  2018-12-10       Impact factor: 2.298

6.  Incidence, determinants and consequences of delirium in older patients after transcatheter aortic valve implantation.

Authors:  Jeannette A Goudzwaard; Marjo J A G de Ronde-Tillmans; Tom A J de Jager; Mattie J Lenzen; Rutger-Jan Nuis; Nicolas M van Mieghem; Joost Daemen; Peter P T de Jaegere; Francesco U S Mattace-Raso
Journal:  Age Ageing       Date:  2020-04-27       Impact factor: 10.668

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.